Metformin Hydrochlorid Eg (Eurogenerics)

Metformin Hydrochloride, the active ingredient in Metformin Hydrochlorid Eg (Eurogenerics), is a Biguanide presented as an oral tablet formulation for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus. GNH USA supplies Metformin Hydrochlorid Eg (Eurogenerics) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Hydrochloride is employed in the management of type 2 diabetes mellitus, a disorder of glucose metabolism.

- Type 2 diabetes mellitus: improves overall glycemic control by lowering fasting and post‑prandial blood glucose. - Adjunct therapy in type 2 diabetes: added when diet, exercise and lifestyle measures alone are insufficient. - First‑line monotherapy for type 2 diabetes: can be initiated as the initial oral agent in newly diagnosed patients.

Metformin Hydrochloride may cause a range of adverse reactions, most of which are related to the gastrointestinal tract, while rare but serious events require prompt medical attention.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Abdominal discomfort: cramping or pain. - Metallic taste: transient alteration in taste perception. - Weight loss: modest reduction in body weight. - Loss of appetite: decreased desire to eat.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening buildup of lactic acid. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: abnormal liver enzyme elevations. - Hypoglycemia: uncommon when used alone but possible with other glucose‑lowering agents. - Vitamin B12 deficiency: long‑term therapy may reduce B12 absorption.

Metformin Hydrochloride requires careful consideration of patient‑specific factors and monitoring to minimize risks. - Renal function: assess creatinine clearance before initiating and periodically thereafter. - Hepatic impairment: avoid use in patients with significant liver disease. - Risk of lactic acidosis: discontinue before any radiographic contrast procedures. - Vitamin B12 monitoring: consider periodic assessment during long‑term therapy. - Contraindications: do not use in patients with known hypersensitivity to metformin. - Store below 25°C: keep in the original packaging, protect from moisture and heat.

Metformin Hydrochloride can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate lactic acidosis; withhold metformin before and after the procedure. - Cimetidine: can increase metformin plasma concentrations, raising the risk of adverse effects.

Moderate Interactions (Monitor Closely): - Alcohol: excessive intake may potentiate lactic acidosis. - Diuretics (loop or thiazide): may affect renal function and increase metformin accumulation. - Warfarin: may require closer INR monitoring due to potential interaction.